EX-32.1 7 nrbo-20221231xex32d1.htm EX-32.1

​

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

​

​

In connection with the Annual Report of NeuroBo Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2022 as filed with the Securities and Exchange Commission (the “Report”), I, Joseph Hooker, Interim President and Chief Executive Officer, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

​

(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

​

(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

​

April
March 30, 2023 /s/ Joseph Hooker
Joseph Hooker
Interim President, and Chief Executive Officer (Principal Executive Officer and Principal Financial Officer)

​